ClinicalTrials.gg
CompletedNCT03465878Updated Jun 18, 2020Results posted

A Study of LY900014 in Participants With Type 1 Diabetes Mellitus

A Phase 1 interventional study of LY900014 and Insulin Lispro in Type 1 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 2 sites in 2 countries. Open to participants aged 6 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-06-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
6 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.

Enrollment
28th of 69
56 · median 38
Started
2018
with 7 others
Phase 1
22 of 69
none open now
Registered
45th of 69
by date
Lead sponsor
31 of 69
Eli Lilly and Company

Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 28th largest by enrollment, is one of 8 that started in 2018, is one of 22 in phase 1, and was the 45th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 6 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes mellitus.

There are 2 parts to this study. Part A is investigating how the body processes LY900014 and the effect of LY900014 on blood sugar levels compared to insulin lispro (Humalog) when study treatment is given by subcutaneous injection. Part B of the study is investigating how the body processes LY900014 and the effect of LY900014 on blood sugar levels compared to insulin lispro (Humalog) when study treatment is given by continuous subcutaneous insulin infusion (CSII) pump.

Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 40 days in each part.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
6 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are male or female participants aged 6-64 with Type 1 Diabetes Mellitus (T1DM) for at least 1 year
  • Have a (HbA1c) less than (\<)10.0 percent (%)

Exclusion criteria

Exclusion Criteria:

  • Receiving any oral or injectable medication intended for the treatment of diabetes mellitus other than insulins in the 12 months prior to screening
  • More than one episode of severe hypoglycaemia in the last 6 months
  • Presence of hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease, proliferative retinopathy, uncontrolled celiac disease, uncontrolled hyperthyroidism or hypothyroidism, or adrenal insufficiency
  • Have obvious clinical signs or symptoms of liver disease
  • Have a history of renal impairment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    LY900014-Part A

    Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.

    Drug: LY900014

  • Active comparator
    Humalog (Insulin Lispro)-Part A

    Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.

    Drug: Insulin Lispro

  • Experimental
    LY900014-Part B

    Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.

    Drug: LY900014

  • Active comparator
    Humalog (Insulin Lispro)-Part B

    Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.

    Drug: Insulin Lispro

Interventions

  • Administered via SC injection

    Also known as: Ultra-Rapid Lispro

  • Administered via SC injection

    Also known as: Humalog, LY275585

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part

    Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC(0 -7h)) following Each Treatment Arm for Each Study Part.

    Time frame: Predose, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 90, 120, 150, 180, 240, 300, 360, and 420 minutes postdose

Secondary outcomes

  1. Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part

    Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve (BG∆AUC(0-5h)) Following Each Treatment Arm for Each Study Part.

    Time frame: -30, -15, 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240 and 300 minutes postdose

07

Results

Posted Jun 18, 2020

Participant flow

Participants (pts) who completed Part A but discontinued before the beginning of Part B were replaced by newly enrolled participants in Part B.

Period 1-Part A First Intervention Day 1
Participant flow — Period 1-Part A First Intervention Day 1
MilestoneSequence 1-Part ASequence 2-Part ASequence 1-Part BSequence 2-Part B
Started212100
Received at least 1 dose of study drug212100
Children (2-11 years)7600
Adolescents (12-17 years)7700
Adults (18-64 years)7800
Completed212000
Not completed0100
Withdrew: Withdrawal by subject0100
Period2-Part A Second Intervention Day 1
Participant flow — Period2-Part A Second Intervention Day 1
MilestoneSequence 1-Part ASequence 2-Part ASequence 1-Part BSequence 2-Part B
Started212000
Children (2-11 years)7600
Adolescents (12-17 years)7700
Adults (18-64 years)7700
Completed212000
Not completed0000
Period 1-Part B First Intervention Day 1
Participant flow — Period 1-Part B First Intervention Day 1
MilestoneSequence 1-Part ASequence 2-Part ASequence 1-Part BSequence 2-Part B
Started002019
Received at least 1 dose of study drug002017
Children (2-11 years)0066
Adolescents (12-17 years)0076
Adults (18-64 years)0075
Completed002017
Not completed0002
Withdrew: Withdrawal by subject0001
Withdrew: Physician decision0001
Period2-Part B Second Intervention Day 1
Participant flow — Period2-Part B Second Intervention Day 1
MilestoneSequence 1-Part ASequence 2-Part ASequence 1-Part BSequence 2-Part B
Started002017
Children (2-11 years)0066
Adolescents (12-17 years)0076
Adults (18-64 years)0075
Completed002017
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part

Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC(0 -7h)) following Each Treatment Arm for Each Study Part.

Time frame:
Predose, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 90, 120, 150, 180, 240, 300, 360, and 420 minutes postdose
Reported as:
Geometric mean · Picomoles*hour/Liter (pmol*h/L)
Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part
Picomoles*hour/Liter (pmol*h/L)Children-LY900014-Part AChildren-Humalog-Part AAdolescents-LY900014-Part AAdolescents-Humalog-Part AAdults-LY900014-Part AAdults-Humalog-Part AChildren-LY900014-Part BChildren-Humalog-Part BAdolescents-LY900014-Part BAdolescents-Humalog-Part BAdults-LY900014-Part BAdults-Humalog-Part B
Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part755 ± 15754 ± 17962 ± 17908 ± 21987 ± 20975 ± 21743 ± 17714 ± 17842 ± 20866 ± 161100 ± 351070 ± 35
Statistical analysis
  • Children-LY900014-Part A vs Children-Humalog-Part A · Mixed Models Analysis · p = 0.9813 · Ratio of geometric least squares means: 0.999 · 95% CI 0.918 to 1.09
  • Adolescents-LY900014-Part A vs Adolescents-Humalog-Part A · Mixed Models Analysis · p = 0.1638 · Ratio of geometric least squares means: 1.06 · 95% CI 0.976 to 1.15
  • Adults-LY900014-Part A vs Adults-Humalog-Part A · Mixed Models Analysis · p = 0.7623 · Ratio of geometric least squares means: 1.01 · 95% CI 0.933 to 1.10
  • Children-LY900014-Part B vs Children-Humalog-Part B · Mixed Models Analysis · p = 0.2952 · Ratio of geometric least squares means: 1.04 · 95% CI 0.962 to 1.13
  • Adolescents-LY900014-Part B vs Adolescents-Humalog-Part B · Mixed Models Analysis · p = 0.4052 · Ratio of geometric least squares means: 0.970 · 95% CI 0.901 to 1.04
  • Adults-LY900014-Part B vs Adults-Humalog-Part B · Mixed Models Analysis · p = 0.5314 · Ratio of geometric least squares means: 1.02 · 95% CI 0.948 to 1.11
SecondaryGlucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part

Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve (BG∆AUC(0-5h)) Following Each Treatment Arm for Each Study Part.

Time frame:
-30, -15, 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240 and 300 minutes postdose
Reported as:
Mean · milligrams*hour per deciliter (mg*h/dL)
Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part
milligrams*hour per deciliter (mg*h/dL)Children-LY900014-Part AChildren-Humalog-Part AAdolescents-LY900014-Part AAdolescents-Humalog-Part AAdults-LY900014-Part AAdults-Humalog-Part AChildren-LY900014-Part BChildren-Humalog-Part BAdolescents-LY900014-Part BAdolescents-Humalog-Part BAdults-LY900014-Part BAdults-Humalog-Part B
Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part384 ± 335492 ± 270577 ± 247651 ± 238372 ± 179351 ± 240602 ± 221582 ± 254614 ± 160614 ± 163343 ± 194401 ± 235

Adverse events

Collected over From Baseline to Study Completion (Up to 20 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Children-LY900014-Part A0/13 (0%)0/13 (0%)4/13 (30.8%)
Children-Humalog-Part A0/13 (0%)0/13 (0%)4/13 (30.8%)
Adolescents-LY900014-Part A0/14 (0%)1/14 (7.1%)6/14 (42.9%)
Adolescents-Humalog-Part A0/14 (0%)0/14 (0%)3/14 (21.4%)
Adults-LY900014-Part A0/14 (0%)0/14 (0%)2/14 (14.3%)
Adults-Humalog-Part A0/15 (0%)0/15 (0%)2/15 (13.3%)
Children-LY900014-Part B0/12 (0%)0/12 (0%)6/12 (50%)
Children-Humalog-Part B0/12 (0%)0/12 (0%)4/12 (33.3%)
Adolescents-LY900014-Part B0/13 (0%)0/13 (0%)3/13 (23.1%)
Adolescents-Humalog-Part B0/13 (0%)0/13 (0%)1/13 (7.7%)
Adults-LY900014-Part B0/12 (0%)0/12 (0%)3/12 (25%)
Adults-Humalog-Part B0/12 (0%)0/12 (0%)2/12 (16.7%)
Most frequent serious events
Most frequent serious events
EventChildren-LY900014-Part AChildren-Humalog-Part AAdolescents-LY900014-Part AAdolescents-Humalog-Part AAdults-LY900014-Part AAdults-Humalog-Part AChildren-LY900014-Part BChildren-Humalog-Part BAdolescents-LY900014-Part BAdolescents-Humalog-Part BAdults-LY900014-Part BAdults-Humalog-Part B
InjuryInjury, poisoning and procedural complications0/130/131/140/140/140/150/120/120/130/130/120/12
Most frequent other events
Showing 10 of 28
Most frequent other events
EventChildren-LY900014-Part AChildren-Humalog-Part AAdolescents-LY900014-Part AAdolescents-Humalog-Part AAdults-LY900014-Part AAdults-Humalog-Part AChildren-LY900014-Part BChildren-Humalog-Part BAdolescents-LY900014-Part BAdolescents-Humalog-Part BAdults-LY900014-Part BAdults-Humalog-Part B
Injection site erythemaGeneral disorders2/130/132/141/141/140/150/120/120/130/131/120/12
NasopharyngitisInfections and infestations1/132/131/140/140/140/150/120/120/130/130/120/12
Abdominal painGastrointestinal disorders0/130/130/140/140/140/151/121/120/130/130/120/12
Feeling hotGeneral disorders0/130/130/140/140/140/151/120/120/130/130/120/12
Injection site painGeneral disorders1/130/130/141/140/140/151/120/121/130/131/121/12
Injection site pruritusGeneral disorders0/130/130/140/140/140/150/120/120/130/130/121/12
CystitisInfections and infestations0/130/130/140/140/140/150/120/120/130/130/121/12
Ear infectionInfections and infestations0/130/130/140/140/140/151/120/120/130/130/120/12
GastroenteritisInfections and infestations0/130/130/140/140/140/150/121/120/130/130/120/12
Upper respiratory tract infectionInfections and infestations0/130/130/140/140/140/151/121/120/130/130/120/12

Baseline characteristics

All newly randomized participants of Part A and Part B.

Age, Continuous
Age, Continuous(Years)Part APart BTotal
Mean20.5 ± 15.123.2 ± 11.121.2 ± 14.2
Age, Customized
Age, Customized(Participants)Part APart BTotal
Children (2-11 Years)13316
Adolescents (12-17 years)14216
Adults (18-64 years)15924
Sex: Female, Male
Sex: Female, Male(Participants)Part APart BTotal
Female20828
Male22628
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part APart BTotal
Hispanic or Latino202
Not Hispanic or Latino401454
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part APart BTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American101
White371148
More than one race314
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Part APart BTotal
Canada281038
Germany14418
08

Study locations

2 sites
  • LMC Endocrinology Centres Ltd.
    Toronto, Ontario M4G 3E8, Canada
  • Kinderkrankenhaus auf der Bult
    Hannover, Niedersachsen 30173, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Nov 2019, 19 months.

Results were first posted in Jun 2020, 7 months after primary completion.

Of 98 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 19 months is above that.

Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2018
First posted
Mar 14, 2018
StartActual
Mar 26, 2018
Primary completionActual
Nov 14, 2019
CompletionActual
Nov 14, 2019
Results first posted
Jun 18, 2020
Last update
Jun 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03465878
Responsible party
Sponsor
First posted
Mar 14, 2018
Start date
Mar 26, 2018
Primary completion
Nov 14, 2019
Completion
Nov 14, 2019
Results posted
Jun 18, 2020
Last update
Jun 18, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Lispro

Start the discussion